Durata (NASDAQ:DRTX) is a small biopharmaceutical company engaged in the development of antibiotic drugs. The company is headed toward an incredibly important milestone - the likely NDA approval of their first drug, Dalvance (dalvabancin), by the end of May. As followers of this company are well aware, the FDA advisory committee recommended approval of dalvabancin back in March by a 12 - 0 vote. In a recent article on Durata by Seeking Alpha contributor Tri Duong, a positive vote by the Ad Com leads to a 91% approval by the FDA. Thus, approval probability is very high and only an administrative glitch would likely delay it.
Dalvance - A Very Brief Background
Dalvance (dalbavancin) is a lipoglycopeptide antibiotic...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|